DOCSLIB.ORG

Introduction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Introduction Interim guidance for poliomyelitis (polio) surveillance network in the context of coronavirus disease (COVID-19) – Update 25 March 2021 Introduction The coronavirus disease (COVID-19) pandemic is an unprecedented global event that has required adjustments to routine surveillance activities for detection of polioviruses to ensure the personal safety of surveillance related personnel in the field and/or laboratory – surveillance officers, laboratory technicians/scientists, healthcare workers, and community members. This document aims to update global guidance on AFP/polio surveillance in the context of the COVID-19 pandemic and is a technical replacement for the Interim guidance for poliomyelitis (polio) surveillance network in the context of coronavirus disease (COVID-19)1 published in May 2020. The previous guidance included standard operating procedures that specified how to modify the following surveillance-specific activities as the risk mitigation measures and effects of the COVID-19 pandemic continued to evolve: • Active acute flaccid paralysis (AFP) surveillance • Investigation of poliovirus type 2 isolation in the environment • Community based surveillance for polio • Acute flaccid paralysis (AFP) case investigation • Detailed polio case investigation • Guidance on the prioritization for storage, shipment, and testing of polio surveillance samples Since the COVID-19 pandemic began over a year ago, mitigation measures to prevent the spread of SARS-CoV-2 have been adopted by countries. Programs including the Global Polio Eradication Initiative (GPEI) have implemented these measures, which have now become the “new normal” for operations. The updated guidance aligns with this new way of working. This guidance recommends resumption of polio surveillance activities where feasible, per standard GPEI and Global Polio Laboratory Network (GPLN) guidance; however, local, national, and regional variations in SARS-CoV-2 transmission and response should be considered. At the discretion of regional and country leadership, further adaptation of the guidance or specific modification for regional or country context may be needed. The specific objective of this guidance document is to: • Describe measures that can be undertaken to reduce or prevent the spread of SARS-CoV-2 while conducting surveillance activities for detection of polioviruses National polio surveillance programs can conduct surveillance activities as long as these are in accordance with local and national mandates. At all times, polio surveillance personnel should practice safety precautions such as use of personal protective equipment (PPE) and physical distancing when conducting activities. 1 Interim guidance for the poliomyelitis (polio) surveillance network in the context of coronavirus disease (COVID-19). Geneva: World Health Organization, 2020. (https://www.who.int/publications/i/item/WHO-POLIO-20.04) 1 | P a g e As countries implement this guidance and adapt to the local context, the programme must remember not to compromise on the safety and security of surveillance officers and other polio staff and adhere to the principles of “do no harm” and “duty of care” by limiting direct contact with patients/individuals, maintaining appropriate physical distancing and ensuring that all health care workers are fully trained and have appropriate PPE2,3 . Recommendations for in-person activities Polio surveillance personnel who conduct field polio surveillance activities should be provided with, as a minimum, hand sanitizers or handwashing supplies if access to clean water is available, face masks, and disinfectant solution to clean surfaces. Protective measures in place for polio surveillance prior to the COVID-19 pandemic such as gloves for collecting stool specimens or other PPE for environmental surveillance sample collection will similarly protect from SARS-CoV-2 transmission. In situations where programme personnel are at increased risk of contracting COVID-19 (e.g., during case specimen collection and handling, in-person case investigations and active surveillance visits), additional measures including the provision of gloves should be considered. Polio surveillance personnel should receive the COVID-19 vaccine in accordance with national/Ministry of Health instructions and prioritization. General • Maintain at least 1-meter (approximately 3 feet) distance between individuals and, if not possible, ensure proper use of non-medical mask • Wear non-medical mask in indoor (e.g. offices, shared workplaces, clinics) regardless of whether physical distancing of at least 1 metre can be maintained or outdoor settings where physical distancing of at least 1 metre cannot be maintained4 • Perform hand hygiene after conducting in-person activities with soap and water or hand sanitizer containing 60-80% alcohol Visiting health facilities • Conduct activities (i.e., medical records review) in a well-ventilated space, outdoors and/or by maintaining recommended physical distancing as often as possible • All personnel should practise good hand hygiene5 before and after each direct person encounter 2 Overview of public health and social measures in the context of COVID-19: interim guidance. Geneva: World Health Organization; 2020 (https://www.who.int/publications-detail/overview-of-public-health-and-social-measures-in-the-context-of-covid-19). 3 Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: interim guidance. Geneva: World Health Organization; 2020. (https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is- suspected-20200125). 4 Mask use in the context of COVID-19. Geneva: World Health Organization; 2020. Advice on the use of masks in the community, during home care and in healthcare settings in the context of the novel coronavirus (COVID-19) outbreak (who.int) 5 WHO save lives, clean your hands in the context of COVID-19. Geneva: World Health Organization; 2020. https://www.who.int/publications/m/item/who-saves-lives-clean-your-hands-in-the-context-of-covid-19 2 | P a g e • Disinfect any surfaces with a chlorine or alcohol-based solution before and after use6 Visiting communities • Conduct activities (i.e., interviews, visual assessments) in a well-ventilated space, outdoors and/or by maintaining recommended physical distancing as often as possible. • Avoid crowded areas by – o Limiting the number of people involved in an activity to those who are essential o Conducting virtual/telephone activities where possible • All personnel should practise good hand hygiene before and after each direct person encounter Trainings and meetings • Recommend continuing to conduct maximally virtual meetings and trainings until there are compelling situations. In-person meetings and training sessions should be conducted in well- ventilated (e.g., open windows) and frequently disinfected areas; and reports of such activities MUST mention reasons (for in person training ) • Limit number of people gathered according to national or local guidelines7 • Consult web-based GPEI training modules on basics of surveillance that are suited to the ‘new norms’. These are most likely to be available by Xxxx, 2021. • Considerations for implementation Polio surveillance activities implemented in the context COVID-19 require special considerations to ensure the safety of polio staff and community members. The following principles should be reviewed and incorporated into practice by regional and country leadership overseeing activities (general) and staff executing activities (individual). General8 • Tailor strategies to enable safest, most effective implementation of surveillance activities. This may translate to web or telephone-based implementation in areas with community transmission. • Involve community leaders in surveillance activities conducted in the community; work with the community to minimize risk of SARS-CoV-2 transmission during surveillance activities • Ensure adequate access to PPE supplies, e.g. masks, hand sanitizer or hand washing units with soap and water Individual 6 Cleaning and disinfection of environmental surfaces in the context of COVID-19. Geneva: World Health Organization; 2020. https://www.who.int/publications/i/item/cleaning-and-disinfection-of-environmental-surfaces-inthe-context-of-covid-19 7 Interim Guidelines for Frontline Workers on Safe Implementation of House-To-House Vaccination Campaigns (25 June 2020). Geneva: World Health Organization; 2020. INTERIM guidelines FOR FRONTLINE WORKERS on safe implementation of house-to-house vaccination campaigns (25 JUNE 2020) (polioeradication.org) 8 Framework for decision-making: implementation of mass vaccination campaigns in the context of COVID-19. Geneva: World Health Organization; 2020. Framework for decision-making: implementation of mass vaccination campaigns in the context of COVID-19 (who.int) 3 | P a g e • In-person surveillance activities should be undertaken if steps can be made to mitigate SAR-CoV-2 transmission • An individual’s own comfort and risk level including vulnerabilities like age and other health conditions should be assessed before undertaking any surveillance activities • Adhere rigorously to PPE measures and risk mitigation measures (e.g., handwashing, physical distancing) to protect surveillance officers and other polio staff against SARS-CoV-2 and other pathogens transmitted via person-to-person9 • Avoid meeting with any individuals with symptoms of COVID-19 and encourage people
Load more

Recommended publications
  • Rotavirus Vaccine for the Prevention of Rotavirus Gastroenteritis Among Children
    March 19, 1999 / Vol. 48 / No. RR-2 Recommendations and Reports Rotavirus Vaccine for the Prevention of Rotavirus Gastroenteritis Among Children Recommendations of the Advisory Committee on Immunization Practices (ACIP) Continuing Education Examination Education Continuing Inside: U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Disease Control and Prevention (CDC) Atlanta, Georgia 30333 The MMWR series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333. SUGGESTED CITATION Centers for Disease Control and Prevention. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-2):[inclu- sive page numbers]. Centers for Disease Control and Prevention....................Jeffrey P. Koplan, M.D., M.P.H. Director The material in this report was prepared for publication by National Center for Infectious Diseases.................................. James M. Hughes, M.D. Director Division of Viral and Rickettsial Diseases ................. Brian W. J. Mahy, Ph.D., Sc.D. Director National Immunization Program ...........................................Walter A. Orenstein, M.D. Director Epidemiology and Surveillance Division ...........................John R. Livengood, M.D. Director The production of this report as an MMWR serial publication was coordinated in Epidemiology Program Office.................................... Stephen B. Thacker, M.D., M.Sc. Director Office of Scientific and Health Communications ......................John W. Ward, M.D. Director Editor, MMWR Series Recommendations and Reports................................... Suzanne M. Hewitt, M.P.A. Managing Editor Valerie R. Johnson Project Editor Morie M. Higgins Visual Information Specialist Vol. 48 / No. RR-2 MMWR i Contents Clinical and Epidemiologic Features of Rotavirus Disease.............................................
    [Show full text]
  • Poliomyelitis and Polio-Encephalitis
    POLIOMYELITIS AND POLIO-ENCEPHALITIS. 151 Postgrad Med J: first published as 10.1136/pgmj.2.22.151 on 1 July 1927. Downloaded from coryza, or gastro-intestinal symptoms such as vomiting and diarrhoea. The lymphatic glands are POLIOMYELITIS enlarged. The temperature rises, often ranging AND POLIO-ENCEPHALITIS.* between 101° and 103°F., and there is general malaise often accompanied by profuse sweating. BY In some cases both local and general symptoms are E. A. COCKAYNE, M.D. OXF., F.R.C.P. LOND., so slight that they may be overlooked and the PHYSICIAN TO THE MIDDLESEX HOSPITAL; PHYSICIAN rise of temperature may be very small. After TO OUT-PATIENTS, HOSPITAL FOR SICK CHILDREN, lasting from one to four days the illness may end GREAT ORMOND-STREET. at this stage. If it continues headache, drowsiness POLIOMYELITIS, like other specific fevers, has its and irritability, pain and stiffness in the back, special age and seasonal incidence; it is commonest accompanied sometimes by twitching of the in the late summer and early autumn, and the limbs or retraction of the head, may develop, and majority of its victims are children between the these indicate involvement of the meninges. ages of 1 and 5 years. The earliest symptoms are Hyperssthesia of skin and muscles may also be constitutional, malaise and fever, and in some prominent. Then if the grey matter of the central cases the involvement of the nervous system, to nervous system becomes infected, weakness, paresis, which it owes its name, never occurs. Such and paralysis of muscles develops. Paralyses cases are usually regarded as abortive, but in may appear to be dramatically sudden, but my opinion this view is not the correct one.
    [Show full text]
  • SOS – Save Our Shoulders: a Guide for Polio Survivors
    1 • Save Our Shoulders: A Guide for Polio Survivors A Guide for Polio Survivors S.O.S. Save Our Shoulders: A Guide for Polio Survivors by Jennifer Kuehl, MPT Roberta Costello, MSN, RN Janet Wechsler, PT Funding for the production of this manual was made possible by: The National Institute for Disability and Rehabilitation Research Grant #H133A000101 and The U.S. Department of the Army Grant #DAMD17-00-1-0533 Investigators: Mary Klein, PhD Mary Ann Keenan, MD Alberto Esquenazi, MD Acknowledgements We gratefully acknowledge the contributions and input provided from all of those who participated in our research. The time and effort of our participants was instrumental in the creation of this manual. Jennifer Kuehl, MPT Moss Rehabilitation Research Institute, Philadelphia Roberta Costello, MSN, RN Moss Rehabilitation Research Institute, Philadelphia Janet Wechsler, PT Moss Rehabilitation Research Institute, Philadelphia Mary Klein, PhD Moss Rehabilitation Research Institute, Philadelphia Mary Ann Keenan, MD University of Pennsylvania, Philadelphia Alberto Esquenazi, MD MossRehab Hospital, Philadelphia Cover and manual design by Ron Kalstein, MEd Albert Einstein Medical Center, Philadelphia Table of Contents 1. Introduction . .5 2. General Information About the Shoulder . .6 3. Facts About Shoulder Problems . .8 4. Treatment Options . .13 5. About Exercise . .16 6. Stretching Exercises . .19 7. Cane Stretches . .22 8. Strengthening Exercises . .25 9. Tips to Avoid Shoulder Problems . .29 10. Conclusion . .31 11. Resources . .31 The information contained within this manual is for reference only and is not a substitute for professional medical advice. Before beginning any exercise program consult your physician. Save Our Shoulders: A Guide for Polio Survivors • 4 Introduction Many polio survivors report new symptoms as they age.
    [Show full text]
  • What Having Had Polio Causes, Might Cause and Does Not Cause Marny K
    What Having Had Polio Causes, Might Cause and Does Not Cause Marny K. Eulberg, MD, Family Practice, Denver, Colorado Introduction: As time has elapsed since the major poliomyelitis epi- demics ended, following the widespread introduction of the polio vaccines, persons affected by polio, their families and their health- care providers seem to have less and less clear understanding about what symptoms are caused by polio, which are associated with polio and which are not. Many healthcare providers in practice today have had little experience or training in the care of polio survivors, and they studied the basic pathology that the poliovirus causes years ago. Organizations, such as Post-Polio Health International, which exist to provide information to polio survivors, are frequently asked questions Marny K. Eulberg, MD about various symptoms and the relationship to the acute polio. Post-polio groups and expert professionals have indicated that many individuals have been given incorrect or confusing information. Attributing symptoms or changes in symptoms and try to understand them. functioning to one’s previous polio Often a symptom can be caused by when the symptom is, in fact, due to many different mechanisms and a disease or condition that should be sometimes even by a combination treated by an entirely different medi- of factors. cal regime than polio/post-polio is not This article is not meant to be all- only not helpful but may be danger- inclusive and list every possible cause/ ous. Polio clinics can help with symp- disease but to discuss the most com- toms that are polio related and can mon and most frequent conditions.
    [Show full text]
  • COVID-19 Eradication for Vaccine Equity in Low Income Countries
    Perspective COVID-19 Eradication for Vaccine Equity in Low Income Countries DHANYA DHARMAPALAN,1 T JACOB JOHN2 From 1Pediatric Infectious Diseases, Apollo Hospitals, CBD Belapur, Navi Mumbai, Maharashtra; 2Chairman, Child Health Foundation, Vellore, Tamil Nadu. Correspondence to: Dr. Dhanya Dharmapalan, Consultant in Pediatric Infectious Diseases, Apollo Hospitals, CBD Belapur, Navi Mumbai 400 614, Maharashtra. [email protected]. PII: S097475591600340 Note: This early-online version of the article is an unedited manuscript that has been accepted for publication. It has been posted to the website for making it available to readers, ahead of its publication in print. This version will undergo copy-editing, typesetting, and proofreading, before final publication; and the text may undergo minor changes in the final version INDIAN PEDIATRICS 1 JUNE 09, 2021 [E-PUB AHEAD OF PRINT] DHANYA DHARMAPALAN, T JACOB JOHN COVID-19 ERADICATION ABSTRACT The coronavirus disease 2019 (COVID-19) pandemic will transition into endemic phase with perpetual risk of severe disease and high mortality in vulnerable people – the elderly and those with co-morbidities, unless eradicated. Although several vaccines are already available to rich countries, low-income countries face gross vaccine inequity. We propose COVID-19 eradication to address both problems. An eradication program will ensure vaccine equity and international cooperation to establish public health surveillance and high quality laboratory diagnostic services in all countries. Eradication is biologically and technically feasible. We hope the World Health Organization will accept the proposition and design the necessary strategy without delay. Keywords: Herd effect, Herd immunity, SARS-CoV-2. Severe Acute Respiratory Syndrome (SARS) caused by SARS Coronavirus type 1 (SARS-CoV-1) began spreading within China in November, 2002, became pandemic in March 2003, and affected 29 countries, with 8096 cases and 774 deaths [1].
    [Show full text]
  • Attenuation of Human Respiratory Syncytial Virus by Genome-Scale Codon-Pair Deoptimization
    Attenuation of human respiratory syncytial virus by genome-scale codon-pair deoptimization Cyril Le Nouëna,1, Linda G. Brocka, Cindy Luongoa, Thomas McCartya, Lijuan Yanga, Masfique Mehedia, Eckard Wimmerb,1, Steffen Muellerb,2, Peter L. Collinsa, Ursula J. Buchholza,3, and Joshua M. DiNapolia,3,4 aRNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; and bDepartment of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY 11794 Contributed by Eckard Wimmer, June 18, 2014 (sent for review February 14, 2014) Human respiratory syncytial virus (RSV) is the most important viral acid coding is unaffected, CPD strains provide the same reper- agent of serious pediatric respiratory-tract disease worldwide. A toire of epitopes for inducing cellular and humoral immunity as vaccine or generally effective antiviral drug is not yet available. the WT pathogen. Recently, the CPD approach has been used We designed new live attenuated RSV vaccine candidates by successfully to attenuate poliovirus, influenza A virus, Strepto- codon-pair deoptimization (CPD). Specifically, viral ORFs were recoded coccus pneumonia, and HIV type 1 (5, 10–13). by rearranging existing synonymous codons to increase the content In the present work, four CPD RSV genomes were designed, of underrepresented codon pairs. Amino acid coding was com- synthesized, and recovered by reverse genetics. The CPD pletely unchanged. Four CPD RSV genomes were designed in recombinant (r) RSVs were attenuated and temperature- which the indicated ORFs were recoded: Min A (NS1, NS2, N, P, sensitive in vitro. Furthermore, we demonstrated that the CPD M, and SH), Min B (G and F), Min L (L), and Min FLC (all ORFs except rRSVs were attenuated and immunogenic in mice and African M2-1 and M2-2).
    [Show full text]
  • Polio Fact Sheet
    Polio Fact Sheet 1. What is Polio? - Polio is a disease caused by a virus that lives in the human throat and intestinal tract. It is spread by exposure to infected human stool: e.g. from poor sanitation practices. The 1952 Polio epidemic was the worst outbreak in the nation's history. Of nearly 58,000 cases reported that year, 3,145 people died and 21,269 were left with mild to disabling paralysis, with most of the victims being children. The "public reaction was to a plague", said historian William O'Neill. "Citizens of urban areas were to be terrified every summer when this frightful visitor returned.” A Polio vaccine first became available in 1955. 2. What are the symptoms of Polio? - Up to 95 % of people infected with Polio virus are not aware they are infected, but can still transmit it to others. While some develop just a fever, sore throat, upset stomach, and/or flu-like symptoms and have no paralysis or other serious symptoms, others get a stiffness of the back or legs, and experience increased sensitivity. However, a few develop life-threatening paralysis of muscles. The risk of developing serious symptoms increases with the age of the ill person. 3. Is Polio still a disease seen in the United States? - The last naturally occurring cases of Polio in the United States were in 1979, when an outbreak occurred among the Amish in several states including Pennsylvania. 4. What kinds of Polio vaccines are used in the United States? - There is now only one kind of Polio vaccine used in the United States: the Inactivated Polio vaccine (IPV) is given as an injection (shot).
    [Show full text]
  • Morbidity and Mortality Weekly Report
    Morbidity and Mortality Weekly Report Weekly February 13, 2004 / Vol. 53 / No. 5 Outbreaks of Avian Influenza A (H5N1) in Asia and Interim Recommendations for Evaluation and Reporting of Suspected Cases — United States, 2004 During December 2003–February 2004, outbreaks of highly In Thailand, influenza A (H5N1) infection was confirmed pathogenic avian influenza A (H5N1) among poultry were in four males, aged 6–7 years, and one female, aged 58 years. reported in Cambodia, China, Indonesia, Japan, Laos, South All five patients died (1). Other cases are under investigation. Korea, Thailand, and Vietnam. As of February 9, 2004, a total of 23 cases of laboratory-confirmed influenza A (H5N1) virus Analysis of Viruses infections in humans, resulting in 18 deaths, had been reported Antigenic analysis and genetic sequencing distinguish in Thailand and Vietnam. In addition, approximately 100 sus- between influenza viruses that usually circulate among birds pected cases in humans are under investigation by national and those that usually circulate among humans. Sequencing health authorities in Thailand and Vietnam. CDC, the World of the H5N1 viruses obtained from five persons in Vietnam Health Organization (WHO), and national health authorities and Thailand, including one sister from the cluster in Viet- in Asian countries are working to assess and monitor the situ- nam, has indicated that all of the genes of these viruses are of ation, provide epidemiologic and laboratory support, and avian origin. No evidence of genetic reassortment between assist with control efforts. This report summarizes informa- avian and human influenza viruses has been identified. If tion about the human infections and avian outbreaks in Asia reassortment occurs, the likelihood that the H5N1 virus can and provides recommendations to guide influenza A (H5N1) be transmitted more readily from person to person will surveillance, diagnosis, and testing in the United States.
    [Show full text]
  • Hepatitis B Vaccine – Frequently Asked Questions (Information from the CDC)
    AAMC Standardized Immunization Form 2020 Hepatitis B Vaccine – Frequently Asked Questions (Information from the CDC) 1. What are the hepatitis B vaccines licensed for use in the United States? Three single-antigen vaccines and two combination vaccines are currently licensed in the United States. Single-antigen hepatitis B vaccines: • ENGERIX-B® • RECOMBIVAX HB® • HEPLISAV-B™ Combination vaccines: • PEDIARIX®: Combined hepatitis B, diphtheria, tetanus, acellular pertussis (DTaP), and inactivated poliovirus (IPV) vaccine. Cannot be administered before age 6 weeks or after age 7 years. • TWINRIX®: Combined Hepatitis A and hepatitis B vaccine. Recommended for people aged ≥18 years who are at increased risk for both HAV and HBV infections. 2. What are the recommended schedules for hepatitis B vaccination? The vaccination schedule most often used for children and adults is three doses given at 0, 1, and 6 months. Alternate schedules have been approved for certain vaccines and/or populations. A new formulation, Heplisav-B (HepB-CpG), is approved to be given as two doses one month apart. 3. If there is an interruption between doses of hepatitis B vaccine, does the vaccine series need to be restarted? No. The series does not need to be restarted but the following should be considered: • If the vaccine series was interrupted after the first dose, the second dose should be administered as soon as possible. • The second and third doses should be separated by an interval of at least 8 weeks. • If only the third dose is delayed, it should be administered as soon as possible. 4. Is it harmful to administer an extra dose of hepatitis B vaccine or to repeat the entire vaccine series if documentation of the vaccination history is unavailable or the serology test is negative? No, administering extra doses of single-antigen hepatitis B vaccine is not harmful.
    [Show full text]
  • An Epidemic of Acute Encephalitis in Young Children
    Arch Dis Child: first published as 10.1136/adc.9.51.153 on 1 June 1934. Downloaded from AN EPIDEMIC OF ACUTE ENCEPHALITIS IN YOUNG CHILDREN BY AGNES R. MACGREGOR, M.B., F.R.C.P.E., AND W. S. CRAIG, B.Sc., M.D., M.R.C.P.E. (From the Departments of Pathology and Child Life and Health, Univer- sity of Edinburgh, and the Western General Hospital, Edinburgh.) This paper is concerned with a small outbreak of illness of an unusual nature occurring in the Children's Unit of the Western General Hospital, Edinburgh. In addition to the clinical interest of the cases, there are features of considerable pathological and epidemiological importance con- nected with the outbreak. Clinical Records. Case 1. I.M.S., female, aged 1 year 7 months, was admitted to the Western General Hospital in March, 1933, at the age of 1 year 3 months. - At this time http://adc.bmj.com/ she was noted as being slightly undersized but well nourished and the liver showed moderate enlargement. Prior to admission she had been treated elsewhere for gonococcal vaginitis: during the three succeeding months her health was good and progress uninterrupted, but a positive Wassermann reaction, present on admission, persisted. On the evening of July 22, 1933, the patient was noticed to be less active than usual and generally ' out of sorts ': her conditiQn remained unchanged throughout the rest of the day, and on the 23rd she was 'Ptill quieter and less responsive to all forms of attention and refused food. By the afternoon on October 2, 2021 by guest.
    [Show full text]
  • Wastewater Based Epidemiology Perspective As a Faster Protocol for Detecting Coronavirus RNA in Human Populations: a Review with Specific Reference to SARS-Cov-2 Virus
    pathogens Review Wastewater Based Epidemiology Perspective as a Faster Protocol for Detecting Coronavirus RNA in Human Populations: A Review with Specific Reference to SARS-CoV-2 Virus Milad Mousazadeh 1,2,†,‡ , Razieh Ashoori 3, Biswaranjan Paital 4 , I¸sıkKabda¸slı 5,‡ , Zacharias Frontistis 6 , Marjan Hashemi 7 , Miguel A. Sandoval 8,9,‡ , Samendra Sherchan 10, Kabita Das 11 and Mohammad Mahdi Emamjomeh 12,* 1 Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran; [email protected] 2 Department of Environmental Health Engineering, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran 3 Department of Environmental Health Engineering, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran; [email protected] 4 Redox Regulation Laboratory, College of Basic Science and Humanities, Odisha University of Agriculture and Technology, Bhubaneswar 751003, India; [email protected] 5 Environmental Engineering Department, Civil Engineering Faculty, Ayaza˘gaCampus, Istanbul˙ Technical University, Istanbul˙ 34469, Turkey; [email protected] 6 Department of Chemical Engineering, University of Western Macedonia, 50132 Kozani, Greece; Citation: Mousazadeh, M.; Ashoori, [email protected] 7 Environmental and Occupational Hazards Control Research Center, Shahid Beheshti University of Medical R.; Paital, B.; Kabda¸slı,I.; Frontistis, Sciences, Tehran, Iran; [email protected] Z.; Hashemi, M.; Sandoval, M.A.; 8 Laboratorio de Electroquímica Medio Ambiental LEQMA, Departamento
    [Show full text]
  • Preventing Polio WHO Myanmar Newsletter Special , 5 August 2019
    Preventing polio WHO Myanmar newsletter special , 5 August 2019 What is polio? Poliomyelitis (polio) is a highly infectious disease that is caused when the polio virus invades the nervous system of an infected person. Polio can cause paralysis and even death. Who is most at risk for polio? Poliovirus usually affects children under 5 years of age who are unvaccinated or under-vaccinated. The virus can also affect or be carried by adolescents and adults. photo credit: Ms Lei Lei Mon, WHO Myanmar The child or individual suspected of polio may A child receives oral polio vaccine at Thandaung township, complain of sudden onset of weakness of arms Kayin State, 21 July 2019 and/or legs. Oral polio vaccine is the vaccine Is there a cure for polio? recommended for polio eradication Can it be prevented? There is no cure for polio. The disease can severely paralyze, or even kill, an infected child. Is the polio vaccine safe? Oral polio vaccine is one of the safest vaccines Polio can be prevented by immunizing a child with ever developed. It is so safe it can be given to sick approrpiate vaccination. There are currently two children and newborns. Since 1961, when oral effective polio vaccines, the inactivated poliovirus polio vaccine was introduced, two billion children vaccine (IPV) and the live attenuated oral polio have been immunized against polio globally. vaccine (OPV). This is estimated to have saved at least 16 million children from permanent paralysis by polio, world- wide. It is also safe to administer multiple doses of polio vaccine to children.
    [Show full text]